Kim, Stanley A.,Giamarellos-Bourboulis, Evangelos J.
申请号：
AU2018220862
公开号：
AU2018220862A1
申请日:
2018.02.16
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds interleukin-1α (IL-1α). Disclosed is the use of an antibody targeting and neutralizing interleukin 1 alpha (IL-1α), for the treatment of hidradenitis suppurativa (HS) in a human subject having lesions caused by the disease. More specifically, the use of the monoclonal antibody MABp1 is shown to be effective in reducing the number and/or size of inflammatory lesions in hidradenitis suppurativa.
